Abstract B108: CXCR4 inhibition reprograms immune checkpoint networks and enhances anti-tumor immunity in patient-derived pancreatic cancer organoid–PBMC co-cultures
Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immunotherapy because of its immunosuppressive, T-cell–excluded microenvironment. Immune checkpoint blockade, alone or with chemotherapy, has shown limited efficacy, likely due to redundant suppressive pathways. CAF-derived CXCL12 acting throug...